This is a translational clinical study aiming to develop approaches to process effectively human tissues and identify biomarkers for painful and non-painful chemotherapy-induced peripheral neuropathy (CIPN). This study will involve obtaining two skin biopsies representing affected and non-affected parts of each patient’s limb. Painful and non-painful neuropathies will be determined by a variety of standard approaches implemented by a neurologist Dr. Bhavaraju-Sanka.  

This will be a long-term multi-center study to comprehensively study patients with primary liver cancer (PLC).

To assess the efficacy of ABBV-400 in each solid tumor indication, including advanced or metastatic hepatocellular (HCC), biliary tract cancer (BTC), pancreatic ductal adenocarcinoma (PDAC), esophageal squamous cell carcinoma (ESCC), triple negative (TN) breast cancer (BC), hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) BC, and head and neck squamous cell carcinoma (HNSCC). The purpose of this study is to evaluate ABBV-400 in subjects with select solid tumors. This study will consist of multiple cohorts with each cohort investigating ABBV-400 at 3 mg/kg Q3W.